{"organizations": [], "uuid": "cd783c4c9ccecb76a91957b643bf4ca440be00b8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180117.html", "section_title": "Archive News &amp; Video for Wednesday, 17 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biolinerx-announces-partial-monoth/brief-biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-cancer-idUSFWN1PC0YH", "country": "US", "domain_rank": 408, "title": "BRIEF-Biolinerx Announces Partial Monotherapy Results From Phase 2A Combat Study In Pancreatic Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-17T21:00:00.000+02:00", "replies_count": 0, "uuid": "cd783c4c9ccecb76a91957b643bf4ca440be00b8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biolinerx-announces-partial-monoth/brief-biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-cancer-idUSFWN1PC0YH", "ord_in_thread": 0, "title": "BRIEF-Biolinerx Announces Partial Monotherapy Results From Phase 2A Combat Study In Pancreatic Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "bioline rx ltd", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 17 (Reuters) - Bioline Rx Ltd:\n* BIOLINERX ANNOUNCES PARTIAL MONOTHERAPY RESULTS FROM PHASE 2A COMBAT STUDY IN PANCREATIC CANCER\n* BIOLINE RX LTD - DATA TO BE PRESENTED AT UPCOMING ASCO-GI CONFERENCE; TOPLINE CLINICAL RESULTS EXPECTED BY H2 2018 AS PLANNED\n* BIOLINE RX LTD - BL-8040 MONOTHERAPY RESULTED IN INCREASED INFILTRATION OF T CELLS INTO TUMOR\n* BIOLINE RX LTD - PARTIAL RESULTS FROM BL-8040 MONOTHERAPY PORTION OF COMBAT TRIAL SHOW THAT BL-8040 WAS SAFE AND WELL-TOLERATED Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T21:00:00.000+02:00", "crawled": "2018-01-18T16:16:38.000+02:00", "highlightTitle": ""}